Compare G & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | KYMR |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | Bermuda | United States |
| Employees | 140000 | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.8B |
| IPO Year | 2007 | 2020 |
| Metric | G | KYMR |
|---|---|---|
| Price | $36.81 | $80.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 26 |
| Target Price | $49.50 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 1.8M | 618.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $2,279,438,000.00 | $39,211,000.00 |
| Revenue This Year | $9.23 | $11.85 |
| Revenue Next Year | $7.26 | $7.79 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.79 | $19.45 |
| 52 Week High | $50.71 | $103.00 |
| Indicator | G | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 49.33 |
| Support Level | $34.79 | $77.78 |
| Resistance Level | $46.04 | $95.90 |
| Average True Range (ATR) | 1.07 | 3.64 |
| MACD | -0.07 | -0.31 |
| Stochastic Oscillator | 22.17 | 53.23 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.